Myocardial viability evaluation using magnetocardiography in patients with coronary artery disease

Case report: Magnetocardiography as a potential method of therapy monitoring in amyloidosis

Amyloidosis is characterized by a disorder of protein conformation and metabolism, resulting in deposits of insoluble fibrils in various organs causing functional disturbances. Amyloidosis can also affect the heart. Cardiac amyloidosis tends to have a poor prognostic outcome if diagnosed at a late stage. Therefore, early diagnosis and initiation of therapy as well as monitoring of treatment response are crucial to improve outcomes and to learn more about its pathophysiology and clinical course. We present an 83-year-old woman with cardiac transthyretin amyloidosis (ATTR) who was treated with tafamidis. The patient significantly improved 18 months after initiation of therapy with regards to exercise capacity and quality of life. In addition to standard diagnostic methods, we used magnetocardiography (MCG) to monitor potential treatment response by detecting changes in the magnetic field of the heart. MCG is a non-invasive method that detects the cardiac magnetic field generated by electrical currents in the heart with high sensitivity. We have recently shown that this magnetic field changes in various types of cardiomyopathies may be used as a non-invasive screening tool. We determined previously that an MCG vector ≥0.052 was the optimal threshold to detect cardiac amyloidosis. The patient's MCG was measured at various time points during therapy. At the time of diagnosis, the patient's MCG vector was 0.052. After starting therapy, the MCG vector increased to 0.090, but improved to 0.037 after 4 months of therapy. The MCG vector reached a value of 0.017 after 5 months of therapy with tafamidis, and then increased slightly after 27 months to a value of 0.027 (<0.052). Data from this case support our previous findings that MCG may be used to monitor treatment response non-invasively. Further research is needed to understand the unexpected changes in the MCG vector that were observed at the beginning of therapy and later in the course. Larger studies will be necessary to determine how these changes in the electromagnetic field of the heart are related to structural changes and how they affect clinical outcomes.

Clinical application of magnetocardiography

Magnetocardiography is a noninvasive contactless method to measure the magnetic field generated by the same ionic currents that create the electrocardiogram. The time course of magnetocardiographic and electrocardiographic signals are similar. However, compared with surface potential recordings, multichannel magnetocardiographic mapping (MMCG) is a faster and contactless method for 3D imaging and localization of cardiac electrophysiologic phenomena with higher spatial and temporal resolution. For more than a decade, MMCG has been mostly confined to magnetically shielded rooms and considered to be at most an interesting matter for research activity. Nevertheless, an increasing number of papers have documented that magnetocardiography can also be useful to improve diagnostic accuracy. Most recently, the development of standardized instrumentations for unshielded MMCG, and its ease of use and reliability even in emergency rooms has triggered a new interest from clinicians for magnetocardiography, leading to several new installations of unshielded systems worldwide. In this review, clinical applications of magnetocardiography are summarized, focusing on major milestones, recent results of multicenter clinical trials and indicators of future developments.

Diagnostic value of magnetocardiography in coronary artery disease and cardiac arrhythmias: a review of clinical data

Despite the availability of several advanced non-invasive diagnostic tests such as echocardiography and magnetic resonance imaging, electrocardiography (ECG) remains as the most widely used diagnostic technique in clinical cardiology. ECG detects electrical potentials that are generated by cardiac electrical activity. In addition to electrical potentials, the same electrical activity of the heart also induces magnetic fields. These extremely weak cardiac magnetic signals are detected by a non-invasive, contactless technique called magnetocardiography (MCG), which has been evaluated in a number of clinical studies for its usefulness in diagnosing heart diseases. We reviewed the basic principles, history and clinical data on the diagnostic role of MCG in coronary artery disease and cardiac arrhythmias.

Detection of non-ST-elevation myocardial infarction using magnetocardiogram: new information from spatiotemporal electrical activation map

BACKGROUND AND AIM

Non-ST-segment elevation myocardial infarction (NSTEMI) cannot be easily detected in the emergency room. We evaluate a method to detect NSTEMI using 64-channel magnetocardiography (MCG).

METHODS

MCG recordings were made in 20 NSTEMI patients (aged 59.7+/-12.4 years), 15 young (aged 26.8+/-3.4 years), and 13 age-matched control subjects (aged 57.3+/-3.6). We evaluated three approaches to analysis, including 1) determination when individual subjects' MCG results fell outside normal ranges for ten MCG parameters, 2) the magnetic field map at the T-wave peak (T-MFM), and 3) a pair of spatiotemporal activation graphs (STAGs) showing two projections of electrical excitation during repolarization.

RESULTS

Significant differences were found between normal controls and patients for all MCG parameters. None of the healthy controls had more than four MCG abnormal parameters, whereas 19 NSTEMI patients (95%) were abnormal in more than four parameters. STAGs and T-MFM also showed clear differences between healthy controls and NSTEMI patients.

CONCLUSIONS

These results suggest that the MCG is sensitive to changes in the cardiac electrical pathway after myocardial infarction as described by these graphs and parameters, and therefore MCG may be a useful tool to detect severe ischemic patients.

Can magnetocardiography detect patients with non-ST-segment elevation myocardial infarction?

BACKGROUND AND AIM

Magnetocardiography (MCG) has been proposed as a noninvasive diagnostic tool to risk-stratify patients with myocardial infarction (MI) and ischemia. The purpose of this study is to find the MCG parameters that are sensitive enough to detect the non-ST-segment elevation myocardial infarction (NSTEMI) patients.

METHODS

MCG data were recorded and analyzed from 165 young controls (mean age = 27.2 +/- 9.0 years), 57 age-matched controls (mean age = 55.9 +/- 10.5 years) and 83 NSTEMI patients (mean age = 59.7 +/- 11.1 years). The MCG recordings were obtained using a 64-channel MCG system in a magnetically shielded room. Statistical analyses were performed for 24 parameters derived from QRS-, R-, T-wave, and ST-T period. Binary boundaries to detect NSTEMI patients out of control subjects were found using the receiver operating characteristic (ROC) curve for each parameter.

RESULTS

Fifteen parameters showed a significant difference (P < 0.05 and P < 0.01) between NSTEMI and both of the control groups. For detection of NSTEMI, the angle of the maximum current and the filed map angle on T-wave peak showed the highest diagnostic performance from 75% to 92% including accuracy, sensitivity, specificity, positive predictive value, and negative predictive value (area under ROC curve = 0.87 approximately 0.93).

CONCLUSIONS

Our study showed that MCG has potential clinical application for detection of NSTEMI and should be further investigated.

Reproducibility of Quantitative Estimate of Magnetocardiographic Ventricular Depolarization and Repolarization Parameters in Healthy Subjects and Patients with Coronary Artery Disease

Magnetocardiography (MCG) has been introduced as an innovative non-invasive diagnostic tool to identify various heart diseases. However, there have been little data on the reliability of MCG parameters. The purpose of this study is to examine the test-retest reliability of different diagnostic parameters derived from MCG. We investigated short-, intermediate-, and long-term reliability of nine parameters from T (max/3)-T (max) interval, and five parameters from each time point such as QRS-wave, the peak of R-, and T-wave were evaluated. Short-term reliability was tested in the youngest 20 subjects (mean age = 26.3 +/- 4.9 years) in three sessions separated by 5 min. Intermediate-term reliability was tested in the 35 subjects with coronary artery disease (CAD) (65.1 +/- 7.1 years) with two recording sessions each in the morning and afternoon, separated by more than four hours. Long-term reliability was tested in seven subjects (37.1 +/- 8.8 years) using seven daily sessions. Interclass correlation coefficients (ICC) showed that test-retest reliability was good to excellent (0.99 > or = ICC > or = 0.80) for six out of nine parameters within T (max/3)-T (max). In addition, all parameters on the peak of R-wave, T-wave, and QRS-wave integrated were good to excellent (0.99 > or = ICC > or = 0.80) except for one parameter of CAD patients showing lower ICC values under 0.7. In conclusion, our study showed that the test-retest characteristics of the studied MCG parameters are generally stable and reliable over periods of minutes to days in subjects with different age spectrums.

Pseudo current density maps of electrophysiological heart, nerve or brain function and their physical basis

Background

In recent years the visualization of biomagnetic measurement data by so-called pseudo current density maps or Hosaka-Cohen (HC) transformations became popular.

Methods

The physical basis of these intuitive maps is clarified by means of analytically solvable problems.

Results

Examples in magnetocardiography, magnetoencephalography and magnetoneurography demonstrate the usefulness of this method.

Conclusion

Hardware realizations of the HC-transformation and some similar transformations are discussed which could advantageously support cross-platform comparability of biomagnetic measurements.

Magnetocardiography for pharmacology safety studies requiring high patient throughput and reliability

Recent guideline drafts of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) underline the necessity to test nonantiarrhythmic drugs for their potential to prolong the QT or the corrected QT (QTc) interval. The implementation of these guidelines requires a large amount of ECG measurements on animals and humans in preclinical and clinical phases of the drug development process. We propose the use of magnetocardiography (MCG) as a complementary method with particular advantages in high-throughput studies, where signal quality and reliability are key factors. Our proposal is based on a review of recent MCG studies investigating the repolarization phase and results of methodological work assessing QT interval parameters from the MCG. The applicability of MCG for pre-clinical in-vivo studies is demonstrated by the ease of measurement in unrestrained non-anesthetized rabbits, guinea pigs, and hamsters..